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Abstract 
Vascular cognitive impairment (VCI), including its severe form vascular dementia (VaD), is the second 
most common form of dementia. The genetic aetiology of sporadic VCI remains largely unknown. 
We previously conducted a systematic review and meta-analysis (MA) of all published genetic 
association studies of sporadic VCI prior to 6 July 2012, which demonstrated that APOE (ε4, ε2) and 
MTHFR (rs1801133) variants were associated with susceptibility for VCI. De novo genotyping was 
conducted in a new independent relatively large collaborative European cohort of VaD (nmax= 549) 
and elderly non-demented samples (nmax= 552). Where available, genotype data derived from 
Illumina’s 610-quad array for 1210 GERAD1 control samples were also included in analyses of genes 
examined. Associations were tested using the Cochran-Armitage trend test: MTHFR rs1801133 (OR= 
1.36, 95% CI 1.16-1.58, p= <0.0001), APOE rs7412 (OR= 0.62, 95% CI 0.42-0.90, p= 0.01), and APOE 
rs429358 (OR= 1.59, 95% CI 1.17-2.16, p= 0.003). Association was also observed with APOE epsilon 
alleles; ε4 (OR= 1.85, 95% CI 1.35-2.52, p= <0.0001); and APOE ε2, (OR= 0.67, 95% CI 0.46-0.98, p= 
0.03). Logistic Regression and Bonferroni correction in a subgroup of the cohort adjusted for gender, 
age and population maintained the association of APOE rs429358 and ε4 allele. 
 
Introduction  
Vascular Cognitive Impairment (VCI) represents a heterogeneous group of related conditions 
involving cognitive decline resulting from cerebrovascular disease or systemic disease that leads to 
inadequate cerebrovascular supply. Vascular dementia (VaD), an older and more commonly used 
term to describe more severe forms of VCI, is widely accepted to represent less than a fifth of all 
dementias and is arguably the second most common form of dementia after Alzheimer’s disease 
(AD). However, there is ongoing debate regarding the validity and utility of distinguishing between 
AD and VaD given the very high presence of cerebrovascular disease in AD [1, 2]. Indeed, it has been 
proposed that VCI will become the foremost cause of dementia given the ageing demographics and 
escalating rates of stroke and ischaemic heart disease [3, 4]. 
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Risk factors for common non-autosomal dominant inherited forms of VCI (i.e. sporadic VCI) strongly 
overlap with risk factors for those associated with AD. These include hypertension, diabetes mellitus, 
smoking, atrial fibrillation, positive family history, age and hypercholesterolaemia[5, 6]. However, as 
yet, little is still known about the extent to which genetic variation contributes to risk of VCI, which 
as is the case in AD, is likely to interact with various environmental influences. 
 
Despite the extensive overlap between risk factors for AD, stroke and VCI, there has not been as 
much research into the molecular and genetic basis of VCI. This contrasts markedly with the volume 
of similar activity that has occurred, and proven beneficial in terms of AD research for over two 
decades[7]. The slower emergence of studies in VaD and VCI is most likely due to the lower 
prevalence and highly heterogeneous nature of VCI, both of which are factors that have also served 
to frustrate development of universally accepted means of VCI classification. This is highlighted by 
the numerous diagnostic and other research-based criteria and guidelines for VCI that have been 
developed to provide constructs for the classification of forms of VCI to facilitate research [4, 8-10] 
but in reality have been used to varying extents. Thus large-scale collaborative endeavours that are 
ordinarily needed to properly study diseases of lower prevalence such as VCI have not yet been 
regularly realised. Furthermore there are issues on the level of interpretation and inference that can 
be made across different smaller-scale studies. As a consequence of these factors, thus far, 
susceptibility genes of VCI, particularly those of small effect most likely remain undiscovered.  
 
A useful, rapid and relatively low cost tool to explore and maximise the amount of information that 
can be extracted from what may be considered to be a number of inadequately powered individual 
studies of VCI is meta-analysis (MA). Recently we used MA to investigate a limited number of 
selected (i.e. most commonly studied) candidate genes, partly suggested by previously reported 
associations with AD, and having cardiovascular properties also relevant to VaD including; 
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Apoliopoprotein (APOE), methylenetetrahydrofolate reductase (MTHFR) and angiotensin converting 
enzyme (ACE) polymorphisms [11-14]. In our previous study [15], we used a combined systematic 
review and MA approach of all published candidate gene studies of sporadic VCI to identify 
potentially important candidate genes for VCI. This allowed us to try and address some of the 
shortcomings of previous studies in terms of statistical power, whilst acknowledging the 
heterogeneous nature of VCI. Associations with increased risk for VCI were found for APOE ε4 (OR= 
1.818, 95% CI 1.611 to 2.053, p= <0.001; N= 3,554 cases, N= 12,277 controls) and MTHFR rs1801133 
(OR= 1.323, 95% CI 1.061 to 1.650, p= 0.013; N= 659 cases, N= 981 controls). There was weak 
evidence of a protective effect for APOE ε2 (OR= 0.885, 95% CI 0.783 to 0.999, p= 0.048; N= 3,320 
cases, N= 10,786 controls). MA of polymorphisms: rs4934 of Alpha-1-antichymotrypsin (ACT, now 
formally referred to as SERPINA3); rs1799752 (intron 16 indel variant) of ACE; rs662 of Paraoxonase 
1 (PON-1); and the rs165932 variant of presenilin-1 (PSEN-1) showed no evidence for association 
[15]. 
 
In general, MA of multiple small studies may also suffer from between-study heterogeneity, or be of 
inferior methodological quality [16], including the use of different clinical diagnostic criteria. Many of 
these factors can give rise to disproportionally larger or small effect sizes for any gene found to be of 
interest. Considering these limitations, we attempted to validate our MA findings by genotyping the 
polymorphisms previously found to be interesting [15], in a uniformly diagnosed unprecedented 
cohort of archival DNA from VaD patients and healthy controls of European decent, thereby 
minimising variation in methodology and interpretation.  
 
Materials and Methods  
The collaborative cohort consists of archival samples from the United Kingdom (UK) (n=278) and 
Italy (n=823). Age and gender was available for a subsection of the cohort: mean age VaD 78.74 ± 
0.32 (n= 509), 232 males/296 females; mean age controls 76.83 ± 0.43, (n= 513), 233 males/316 
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females. VaD cases were clinically diagnosed according to NINDS-AIREN criterion [8]. A sample of 
549 VaD cases and 552 controls were genotyped using Sequenom iPLEX Gold (97.7% success rate) 
for a number of polymorphisms (see Table 1). Polymorphism rs4343 in ACE was genotyped as a 
proxy for the ACE I/D [17]. SERPINA3 (ACT) rs4934 was genotyped using Taqman 
(TaqMan C_2188895_10) and analysed using Sequence Detection Software version 2.4. All SNPs 
were concordant for HWE at P>0.001. SNPs rs429358 and rs7412 were directly genotyped and 
APOE epsilon alleles calculated – in brief the T allele at both APOE SNPs identified the ε2 allele, 
whereas the C allele at both positions constitutes the ε4 allele. The T allele at rs429358 and the C 
allele at rs7412 identify the ε3 allele, which is the most common allele in the general population[18]. 
Genotype data from an additional 1210 non-demented elderly individuals (451 males/759 females), 
from UK (n= 830), Northern Ireland (n= 110), Germany (n= 37) and United States (n= 233) that were 
collected as part of the GERAD1 consortium [19] that were used in AD Genome Wide Association 
Studies (GWAS) genotyped on the Illumina 610-quad chip (as described [19]), was available for 
inclusion in the analysis for MTHFR rs1801133 and PON-1 rs662. Age was available for 1133 
individuals; mean 76.34 ± 0.20. Genetic association of susceptibility to VaD were independently 
evaluated using the test for trend implemented in PLINK [20], with logistic regression (LR) analysis 
for age, gender, and population. A p-value <0.05 was considered nominal evidence for statistical 
significance and supportive of our previous findings [15]. SNP-SNP interactions were also analysed in 
426 cases and 1730 controls using PLINK ALL x ALL epistasis mode with the odds ratio calculated for 
interaction and p values adjusted for the multiple tests performed.  
 
Results  
Associations were identified using the Cochran-Armitage trend test for MTHFR rs1801133 (OR= 1.36, 
95% CI 1.16 to 1.58, p= 0.000095), APOE rs7412 (OR= 0.62, 95% CI 0.42 to 0.90, p= 0.01), and APOE 
rs429358 (OR= 1.59, 95% CI 1.17 to 2.16, p= 0.003) (Table 1). Association was also observed with 
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APOE epsilon alleles (ε4: OR= 1.85, 95% Cl 1.35 to 2.52, p= 0.00005; ε2: OR= 0.67, 95% CI 0.46 to 
0.98, p= 0.03); allelic distributions are provided in Table 2. 
 
APOE and MTHFR associations were robust to Bonferroni correction, although logistic regression 
analysis in a subgroup of the cohort adjusted for gender, age and population reduced the strength of 
all associations (Table 1). However, associations for APOE rs429358 (OR= 1.66, 95% CI 1.19 to 2.32, 
p= 0.003) and ε4 allele (OR= 1.61, 95% CI 1.52 to 1.72, p= 0.0001) were robust to these adjustments.  
 
There was no evidence of association between VCI risk and variants in a number of other genes that 
were included in our previous MA study and which here also showed lack of association: rs4934 of 
ACT; rs1799752 of ACE; rs662 of PON-1; and rs165932 of PSEN-1 (Table 1).  
 
Epistasis, defined typically as the interaction between different genes, has revealed many novel 
biological insights for complex disease genetics in recent years. The presence of an allele at one SNP 
loci may interact with alleles at other loci to exert a complementary or specific effect on gene 
expression and / or function.  For example, genes involved may be part of multi-component 
proteins, the same biological pathway, or disease mechanism and exert modifier effects on 
phenotypes. As the genes investigated in this study have been suggested to contribute to VCI, we 
evaluated if SNPs demonstrated independent effects. Using the integrated epistasis approach 
implemented in PLINK (All x ALL command) we tested pairwise combinations of all SNPs across all 
genes for 426 case and 1730 control individuals; no SNP-SNP interaction was statistically significant 
following Bonferroni correction for multiple testing (data not shown). 
 
Discussion 
This study provides supportive evidence, in an independent European cohort of VaD patients and 
non-demented elderly, of association between variants in APOE and MTHFR and susceptibility for 
8 
 
VaD, that validate previous findings for these genes demonstrated by MA [15]. In agreement, we 
found no association for PON-1 rs662, SERPINA3 (ACT) rs4934; PSEN-1 rs165932 or ACE rs1799752 as 
investigated in our previous MA [15]. This supports the utility of MA as a method to maximise the 
amount of information that can be extracted from a series of published unrelated and small case-
control association studies, which individually only allow for limited interpretation because of low 
statistical power.  In a subsequently published MA, the same findings for these SNPs were reported, 
albeit with the inclusion of varying studies[14]. 
 
APOE  
Apoliopoprotein (APOE) plays a key role in lipid metabolism of cholesterol and triglycerides used to 
support synaptogenesis and the maintenance of synaptic connections [21]. APOE has also been 
associated with increased risk of cerebral amyloid angiopathy [22, 23] as well as cardiovascular and 
cerebrovascular atherosclerosis, coronary heart disease, and high total serum cholesterol. 
Collectively the role of APOE in a number of vascular conditions, each of which could contribute to 
VCI, clearly makes APOE a strong candidate gene for VCI risk. There have also been numerous 
studies exploring possible association of APOE ε4 with ischaemic stroke, as recently reviewed by 
Stankovic and Majkic-Singh, however, results on this thus far are conflicting [24].  
 
Our published MA of 63 cohorts totalling 3,554 cases and 12,277 controls showed that APOE ε4 was 
associated with increased risk of VCI[15]. Separate MA of people who were classified against specific 
definitions of VaD (OR= 1.913, 95% CI 1.683 to 2.173, p= <0.001; N= 2,422cases, N= 9,722 controls) 
also showed evidence of association. Stratification of APOE ε4 data by ethnicity also showed 
evidence of association with Asian, and European groups (OR= 1.939, 95% CI 1.576 to 2.386, p= 
<0.001; N= 1,268 cases, N= 4,078 controls). The association we previously identified by MA with 
susceptibility for VaD in Europeans was further supported in this study that comprised a large 
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European cohort; of particular note, the odds ratio in this study (OR= 1.85) is strikingly similar to that 
previously reported (OR= 1.82) for VCI. 
 
Our previously published MA of APOE ε2 revealed a protective effect against VaD and in the analysis 
of all cohorts under a broader VCI term.  The protective effect of APOE ε2 against VaD (OR= 0.812 
95% CI 0.698 to 0.945, p= 0.007; N= 2,247 cases, N= 8,967 controls) was further supported in the 
current case-control study although statistical evidence was only weak (OR= 0.67, 95% CI 0.46 to 
0.98, p= 0.03). APOE ε2 may have a protective effect in coronary artery disease, a disease mediated 
by altered lipoprotein levels, inflammatory and immune activities [25]. 
 
MTHFR rs1801133  
Methylenetetrahydrofolate reductase (MTHFR) is a key rate-limiting enzyme in the metabolism of 
homocysteine (Hcy). The rs1801133 (also known as C677T) polymorphism of MTHFR has been 
associated with reduced enzyme activity and increase serum Hcy levels [26]. It has also been linked 
to several vascular diseases including risk of coronary heart disease and hypertension [27], as well as 
with cognitive impairment [28]. One of the largest MA of 32 published articles (6110 cases/8760 
controls) that investigated this polymorphism in relation to risk of ischaemic stroke/TIA, found that 
the T allele was associated with increased risk of stroke in a graded, dose-dependent manner (T 
allele pooled OR= 1.17; 95% CI 0.09–1.26; TT genotype pooled OR= 1.37; 95% CI 1.15–1.64)[29].  
 
There have been conflicting findings regarding the association between this MTHFR polymorphism 
with stroke, however seven out of 11 MA of stroke that have been previously  undertaken have 
shown an association for C677T [24]. The discrepancies may relate to the fact that the C677T 
polymorphism varies in different ethnic populations, ranging from less than 1% to 21% [30]. 
Furthermore, an association of MTHFR rs1801133 with AD was only found when the co-occurrence 
of APOE ε4 was also included in the analysis [31] suggesting an epistatic interaction. Indeed a similar 
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observation was also found for IL-6 rs1800795 in both AD and VaD [32]. Of particular interest is that 
analysis of the MTHFR rs1801133 by HaploReg version 2 [33] reveals multiple epigenetic effects for 
this SNP in a European population. Characterising the downstream effects of genetic mutations 
associated with disease is challenging.  One approach is to evaluate associations between disease-
associated SNPs and the expression levels of local genes (cis effects) and downstream consequences 
that are more distant from the target SNP (trans effects). Westra and colleagues [34] performed a 
systematic evaluation of expression quantitative trait loci (eQTLs) using next generation sequencing 
in >8,000 individuals; their results were published in Nature Genetics and made publicly available, 
thus providing a rich resource for researchers.  We interrogated this valuable dataset for putative 
functionality of top-ranked SNPs in this study and presented relevant results in Table 3 to support 
biological insights for MTHFR.  Rs1801133 has an impact on both epigenetics and the expression of 
several genes, with this association exceeding traditional genome-wide significance values (Table 3). 
The cis-eQTl links for blood are strongest for Mitofusin 2 gene (MFN2) central to mitochondrial 
fusion and important in the regulation of vascular smooth muscle cell proliferation[35], with defects 
associated with disorders of PNS [36], early events in ischaemic stroke and neurodegeneration [37-
39]. 
 
The results of our MA for MTHFR rs1801133 in VCI also showed an association of the T allele and 
increased risk of VCI and in the smaller MA of VaD cases we also found association (OR= 1.309, 95% 
CI 1.121 to 1.528, p= 0.001; N= 616 cases, N= 981 controls). However, the majority of studies that 
were included in this MA were Asian and only 2 studies were Caucasian, with stratified analysis 
showing that Asian but not Caucasian cohorts (OR= 1.644, 95% CI 0.597 to 4.528), p= 0.336; N= 136 
cases, N= 125 controls) were associated. The current European case-control study, which is larger 
than the combined sample size in the original MA, supported the presence of association with VaD 
and now provides evidence of association in Caucasians (OR= 1.36, 95% CI 1.16 to 1.58, p= 0.0001). 
The odds ratio in this study (OR= 1.36) is similar to the VCI association (OR= 1.32) previously 
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reported, suggesting a similar effect size for both phenotypes, however it should be noted that the 
LR model accounting for age, gender and population in a subsection of the cohort did not show 
evidence of association in the current collection.  
 
In this study of European subjects, there was no evidence of an epistatic interaction between APOE 
and MTHFR polymorphisms, supporting the hypothesis that MTHFR might serve as an independent 
genetic risk factor for VCI. In future studies of VCI, it is worth considering the testing of epistasis in a 
routine manner, where statistical power may allow, to avoid missing clues to risk variants that might 
otherwise be overlooked. 
 
While there was no evidence of association for SERPINA3 (ACT) rs4934 and PSEN-1 rs165932, the 
lack of association with either may relate to the fact most of the biological evidence of the potential 
involvement of both resultant proteins is more related to their roles in aspects of AD and in 
particular that of Aβ peptide pathology [40] that is not part of the main neuropathology of VaD. Yet, 
the function of SERPINA3 might have been more plausible as an acute phase protein that is released 
in response to inflammatory stimuli that have been suggested in early stages of dementia [41].   
 
The PON-1 rs662 and ACE rs1799752 were arguably stronger candidate genes for VCI since 
Paraoxonase 1 (PON-1) has a vascular function as a component of high-density lipoprotein (HDL) but 
is also important for Hcy metabolism while angiotensin converting enzyme (ACE) plays an important 
part in the regulation of systemic blood pressure and fluid electrolyte balance with hypertension one 
of the biggest risk factors for VCI [42]. With respect to PON-1, despite links to Hcy metabolism, 
association with ischemic stroke [43] and synergistic interactions between genes of related 
processes shown in coronary artery disease patients [44], in this study we found no evidence of 
epistatic interactions. In contrast, the D allele of ACE has been suggested, albeit with many 
conflicting studies, to be associated with risk factors for VCI including; myocardial infarction, stroke, 
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cardiovascular disease, essential hypertension, diabetes mellitus and leukoaraiosis in patients with 
ischemic stroke [45]. Yet we found no evidence here, nor in the previous MA study to support any 
association, in agreement with another recent study on VaD [11]. 
 
Study Limitations 
Associations for APOE and MTHFR were robust to Bonferroni correction, although logistic regression 
analysis in a subgroup of the cohort adjusted for gender, age and population reduced the strength of 
all associations (Table 1). However, only a reduced number of cases could be included in this more 
detailed level of analysis, due to the lack of covariate data available for a substantial proportion of 
these archival samples, thus reducing the power to identify such associations. Furthermore, the 
identification of candidate genes by MA is limited and wholly determined by what studies have been 
previously conducted and are suitable for inclusion in the analysis. MA has limitations and biases in 
the same way as any hypothesis-driven approaches towards the discovery of risk genes. More 
recently the use of GWAS has been developed to address this, whilst itself still being limited by the 
amount of gene variants that are included.  
 
Emerging evidence of the genetic aetiology from Genome Wide Associations Studies (GWAS) 
Rs12007229, a single nucleotide variant of no known function located on the X chromosome, which 
is near the androgen receptor gene (OR= 3.7, 95% CI 2.3–5.8, per copy of the minor allele; P= 
1.3×10−8)[46] was identified in 2012 in the first GWAS of VaD. Although a first for this disease it was 
somewhat limited as it involved data from a total of just over 300 incident and prevalent cases of 
VaD that were compared to a Dutch population-based discovery cohort of 5700 subjects. Another 
GWAS reported a novel association with an intronic variant of rs290227 within the spleen tyrosine 
kinase (SYK) gene [47] from a cohort of 87 Korean VaD patients and 200 controls. A comparison of 
these two GWAS could not identify common nucleotide variants[48], yet the potential power of 
GWAS to identify new variants, in relatively small cohorts is highlighted. However, in neither of these 
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GWAS (which are both considerably smaller in sample size to either the original MA or this 
replication study) was there any evidence found to support the involvement of APOE or MTHFR as a 
risk factor. 
 
Conclusions 
We report that variations in both APOE and MTHFR are associated with increased risk of VaD. While 
the potential involvement of MTHFR in VCI risk is interesting, it still needs further independent 
replication. However, the robust association seen here, and in previous MA for the APOE ε4 variant 
as a risk factor strongly support the validity of using APOE variants as a necessary co-variant in 
analysis of other genetic susceptibility factors of VCI, similar to how it has been widely applied in 
genetic studies of AD. GWAS is likely to serve as the most likely method by which to pursue the 
identification of new candidate genes for VCI in the future. However, future successes are also likely 
to be dependent upon the availability of large numbers of samples that will only come via 
collaboration such as has been seen to generate considerable success in recent years in the AD field 
where approximately 32 genes have now been identified [49].  
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 Cochran-Armitage trend test  
with Bonferroni correction 
Logistic regression 
analysis 
Polymorphism Cases Controls OR (95% CI)  p - value BONF OR (95% CI)  p - value 
APOE rs429358 allele C 104/724 82/910 1.59 (1.17-2.16)  0.0026 0.018 
1.66 
(1.19-2.32)  0.003 
APOE rs7412 allele T 43/779 81/905 0.62 (0.42-0.90)  0.012 0.084 
0.70 
(0.46-1.04)  0.078 
MTHFR rs1801133 allele T 363/467 1252/2186 1.36 (1.16-1.58)  0.000095 0.0007 
1.12 
(0.93-1.34)  0.233 
PON-1 rs662 allele G 252/586 1002/2446 1.05 (0.89-1.24)  0.563 1 
1.12 
(0.92-1.35)  0.255 
ACE rs4343 allele A 339/489 396/600 1.05 (0.87-1.27)  0.618 1 
1.07 
(0.87-1.30)  0.524 
PSEN-1 rs165932 allele C 333/489 385/577 1.02 (0.84-0.12)  0.833 1 
1.04 
(0.85-1.27)  0.706 
ACT rs4934 allele G 378/366 469/471 1.04 (0.86 – 1.26)  0.710 1 
1.01 
(0.83-1.24)  0.917 
 
Table 1: Summary analysis of APOE, MTHFR, PON-1, ACE, PSEN-1 and ACT variants in the European cohort. Cochran-
Armitage trend test: no. of minor alleles in VaD cases; no. minor alleles in controls; Bonferroni corrected p-value 
(BONF). Logistic regression with age, gender and population origin as covariates odds ratio (95% confidence 
intervals) and resulting p-value for each respective analysis as detailed in the first column.  
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Alleles Number of cases Number of controls 
Carries any ε2 allele 58 83 
No ε2 allele 471 454 
Carries any ε4 allele 138 86 
No ε4 allele 391 451 
Table 2: APOE epsilon allelic distributions within case and control groups; epsilon allele calls were derived 
from directly typed genotypes for rs429358 and rs7412 SNPs; APOE ε2, (OR= 0.67, 95% CI 0.46-0.98, p= 
0.03) and APOE ε4 (OR= 1.85, 95% CI 1.35-2.52, p= <0.0001).  
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Trans-eQTLs 
p-value SNP Chromosome Base position Minor allele Gene name 
2.062E-6 rs1801133 1 11778965 A PTPRN2 
5.145E-6 rs1801133 1 11778965 A EXOSC6 
1.393E-5 rs1801133 1 11778965 A HOXD11 
Cis-eQTLs 
6.085E-100 rs1801133 1 11778965 A MFN2 
6.216E-80 rs1801133 1 11778965 A PLOD1 
7.818E-32 rs1801133 1 11778965 A MTHFR, C1orf167 
9.470E-13 rs1801133 1 11778965 A KIAA2013, CLCN6 
7.157E-9 rs1801133 1 11778965 A KIAA2013, NPPA 
0.002 rs1801133 1 11778965 A C1orf187 
Table 3: Blood eQTL browser (http://genenetwork.nl/bloodeqtlbrowser/) reports multiple trans and 
cis expression quantitative trait loci for MTHFR rs1801133: protein tyrosine phosphatase, receptor 
type, N polypeptide 2 (PTPRN2); exosome component 6 (EXOSC6); homeobox D11 (HOXD11); 
Mitofusin 2 (MFN2); procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1); 
methylenetetrahydrofolate reductase (MTHFR), chromosome 1 open reading frame 167; KIAA2013; 
chloride channel, voltage-sensitive 6 (CLCN6); natriuretic peptide A (NPPA); dorsal inhibitory axon 
guidance protein (DRAXIN). 
